Close Menu

NEW YORK – Quest Diagnostics received on Tuesday Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 rRT PCR test.

The issuance allows Quest to provide the test for individuals suspected by their healthcare providers of having COVID-19.

On Saturday, the company said that between the capacity provided by its own test as well as other authorized in vitro diagnostic SARS-CoV-2 test kits, it expected to be able to perform roughly 10,000 tests a day by the end of this week and roughly 20,000 tests per day by the end of March.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.